Organogenesis Holdings Inc.

Organogenesis Holdings Inc. (Nasdaq: ORGO) is a commercial-stage regenerative medicine company focused on advanced wound care and surgical biologics. The company went public in December 2018 through a business combination with Avista Healthcare Public Acquisition Corp, a blank-check vehicle sponsored by Avista Capital Partners, in one of the more prominent healthcare SPAC transactions of that year. Organogenesis has since maintained its Nasdaq listing and regular SEC disclosure cadence, most recently filing a quarterly report on Form 10-Q on May 7, 2026. Sign up at SpacDesk for full filing history, sponsor data, and analytics on Organogenesis and hundreds of other SPAC-originated public companies.